Leukemia
Conditions
Keywords
untreated adult acute myeloid leukemia, adult acute erythroid leukemia (M6), adult acute myeloblastic leukemia without maturation (M1), adult acute myeloblastic leukemia with maturation (M2), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), adult acute eosinophilic leukemia, adult acute basophilic leukemia, adult acute megakaryoblastic leukemia (M7), adult acute monocytic leukemia (M5b), adult acute minimally differentiated myeloid leukemia (M0)
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining cytarabine and daunorubicin in treating older patients who have acute myeloid leukemia that has not been previously treated.
Detailed description
OBJECTIVES: * Determine the efficacy of cytarabine and daunorubicin as induction chemotherapy in older patients with previously untreated non-M3 acute myeloid leukemia. * Determine the frequency and severity of toxic effects of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive induction chemotherapy comprising daunorubicin IV continuously over days 1-3 and cytarabine IV continuously over days 1-7. Patients may be treated with a second course of induction chemotherapy beginning on day 19 if remission is not achieved at that time. Patients also receive filgrastim (G-CSF) or sargramostim (GM-CSF) IV or subcutaneously daily beginning on day 15 and continuing until blood counts recover. Patients who achieve remission after the first or second course of induction chemotherapy receive consolidation chemotherapy comprising daunorubicin IV continuously over days 1 and 2 and cytarabine IV continuously over days 1-5. Beginning no earlier than day 19, patients receive a second course of consolidation chemotherapy. Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years. PROJECTED ACCRUAL: Approximately 30-55 patients will be accrued for this study within 8-9 months.
Interventions
BIOLOGICALfilgrastim
induction: 5 mcg/kg/d IV or SC starting apx day 15
BIOLOGICALsargramostim
induction: 250 mcg/m2/d IV or SC starting apx day 1
DRUGcytarabine
ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
DRUGdaunorubicin hydrochloride
ind and consol: 45 mg/m2/d continuous IV days 1-3
Sponsors
National Cancer Institute (NCI)
SWOG Cancer Research Network
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
56 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed acute myeloid leukemia (AML) * No M3 AML or blastic transformation of chronic myelogenous leukemia * Must be enrolled on SWOG-9007 and S9910 protocols PATIENT CHARACTERISTICS: Age: * 56 and over Performance status: * Zubrod 0-3 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 2 times upper limit of normal (ULN) * SGOT or SGPT no greater than 4 times ULN Renal: * Creatinine no greater than 1.5 times ULN OR * Creatinine clearance greater than 40 mL/min Cardiovascular: * LVEF at least 50% by MUGA scan or 2-dimensional echocardiogram * No unstable cardiac arrhythmias * No unstable angina Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior systemic chemotherapy for acute leukemia * Prior hydroxyurea to control high cell counts allowed * Prior low-dose cytarabine (less than 100 mg/m\^2/day) for treatment of myelodysplastic syndrome allowed * At least 30 days since prior chemotherapy and recovered * Concurrent single-dose intrathecal chemotherapy allowed Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR | After induction therapy is completed |
Countries
United States
Outcome results
None listed